All In MedTech

FDA Clearance Tracker · P160048-S031

Eversense® Continuous Glucose Monitoring System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 19, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 19, 2026

Approved

Time to decision

24 days

Received Feb 23, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P160048-S031
Device name
Eversense® Continuous Glucose Monitoring System
Applicant location
Germantown, MD
Received
Feb 23, 2026
Decided
Mar 19, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P160048

Device type

Device class
Class III

Every decision under product code QCD

FDA's approval statement

As written in FDA's record.

Approval of the revised protocol for the post-approval study (PAS) protocol.

Source documents

Other decisions for Senseonics, Incorporated

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.